12:00 AM
Feb 08, 2010
 |  BC Week In Review  |  Company News  |  Other News

Gilead, Teva infectious news

Gilead said it received a paragraph IV certification notification indicating that Teva submitted an ANDA to FDA for a generic version of Gilead's

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >